<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00124644</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000437105</org_study_id>
    <secondary_id>OSU-05020</secondary_id>
    <secondary_id>OSU-2005C0024</secondary_id>
    <secondary_id>NCI-6623</secondary_id>
    <nct_id>NCT00124644</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy and Tipifarnib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia</brief_title>
  <official_title>A Phase I Study of R115777 (Zarnestra) in Combination With Induction Chemotherapy in Patients With Newly Diagnosed, High Risk Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as cytarabine, daunorubicin, and etoposide, work&#xD;
      in different ways to stop the growth of cancer cells, either by killing the cells or by&#xD;
      stopping them from dividing. Tipifarnib may stop the growth of cancer cells by blocking some&#xD;
      of the enzymes needed for cell growth. Giving combination chemotherapy together with&#xD;
      tipifarnib may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of tipifarnib when&#xD;
      given together with combination chemotherapy in treating patients with newly diagnosed acute&#xD;
      myeloid leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose of tipifarnib when given in combination with&#xD;
           induction therapy comprising cytarabine, daunorubicin, and etoposide followed by&#xD;
           consolidation therapy comprising high-dose cytarabine in patients with newly diagnosed&#xD;
           high-risk acute myeloid leukemia.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the qualitative and quantitative toxic effects of this regimen, in terms of&#xD;
           organ specificity, time course, predictability, and reversibility, in these patients.&#xD;
&#xD;
        -  Determine the rate of complete remission in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the remission duration, overall survival, and relapse-free and event-free&#xD;
           survival of patients treated with this regimen.&#xD;
&#xD;
        -  Determine the pharmacokinetics of this regimen in these patients.&#xD;
&#xD;
        -  Correlate pharmacodynamic measurements and levels of tumor necrosis factor-alpha with&#xD;
           clinical response in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of tipifarnib.&#xD;
&#xD;
        -  Induction therapy: Patients receive cytarabine IV continuously on days 1-7; daunorubicin&#xD;
           IV and etoposide IV over 2 hours on days 5-7; and oral tipifarnib twice daily on days&#xD;
           5-12.&#xD;
&#xD;
      Patients undergo bone marrow biopsy on day 17 OR days 17 and 24 (if day 17 bone marrow biopsy&#xD;
      shows suspicious disease). Patients achieving a complete remission (CR) proceed to&#xD;
      consolidation therapy. Patients with residual disease, defined as &gt; 5% leukemic blasts in a&#xD;
      bone marrow of ≥ 20% cellularity, receive a second course of induction therapy comprising&#xD;
      cytarabine IV continuously on days 1-5; daunorubicin IV and etoposide IV over 2 hours on days&#xD;
      4 and 5; and oral tipifarnib twice daily on days 4-9. Patients achieving a CR after a second&#xD;
      course of induction therapy proceed to consolidation therapy. Patients not achieving a CR&#xD;
      after a second course of induction therapy are removed from the study.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of tipifarnib until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2&#xD;
      of 6 patients experience dose-limiting toxicity. An additional 12 patients are treated at the&#xD;
      MTD.&#xD;
&#xD;
        -  Consolidation therapy: Patients receive high-dose cytarabine IV twice daily on days 1,&#xD;
           3, and 5. Treatment repeats approximately every 6-8 weeks for 4 courses.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 3-6 months for up to 5&#xD;
      years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A maximum of 30 patients will be accrued for this study within 10-15&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Withdrawn due to &quot;toxicity&quot; problems&#xD;
  </why_stopped>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>30</enrollment>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>daunorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tipifarnib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>chemotherapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>enzyme inhibitor therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>high-dose chemotherapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed acute myeloid leukemia (AML) according to&#xD;
             the WHO classification system&#xD;
&#xD;
               -  High-risk disease&#xD;
&#xD;
               -  Newly diagnosed disease&#xD;
&#xD;
               -  Patients with secondary AML due to prior chemotherapy for a different malignancy&#xD;
                  are eligible&#xD;
&#xD;
          -  No known inv(16), t(8;21), or t(15;17) cytogenetic abnormality&#xD;
&#xD;
          -  No acute promyelocytic leukemia&#xD;
&#xD;
          -  No CNS leukemia&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 to 59&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 6 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times upper limit of normal&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine normal OR&#xD;
&#xD;
          -  Creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  Ejection fraction &gt; 50% by echocardiogram or MUGA&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  No known HIV positivity&#xD;
&#xD;
          -  No history of allergic reactions attributed to compounds of similar chemical or&#xD;
             biological composition to tipifarnib&#xD;
&#xD;
          -  No allergy to imidazoles (e.g., clotrimazole, ketoconazole, miconazole, or econazole)&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other uncontrolled illness&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent epoetin alfa&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior chemotherapy for AML or myelodysplastic syndromes except hydroxyurea&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No concurrent palliative radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 30 days since prior investigational agents&#xD;
&#xD;
          -  No other concurrent investigational or commercial agents or therapies for the&#xD;
             malignancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William G. Blum, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210-1240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2008</verification_date>
  <study_first_submitted>July 26, 2005</study_first_submitted>
  <study_first_submitted_qc>July 26, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2005</study_first_posted>
  <last_update_submitted>May 1, 2013</last_update_submitted>
  <last_update_submitted_qc>May 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 3, 2013</last_update_posted>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>untreated adult acute myeloid leukemia</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Tipifarnib</mesh_term>
    <mesh_term>Enzyme Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

